NASDAQ:EOLS - Evolus Stock Price, Forecast & News

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings data on Monday, November, 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.55. The company earned $13.17 million during the quarter, compared to the consensus estimate of $5.18 million. View Evolus' Earnings History.

Evolus is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Evolus.

Evolus issued an update on its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $31.8 million.

10 analysts have issued twelve-month target prices for Evolus' stock. Their forecasts range from $13.00 to $37.00. On average, they anticipate Evolus' share price to reach $27.40 in the next year. This suggests a possible upside of 168.9% from the stock's current price. View Analyst Price Targets for Evolus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.

Headlines about EOLS stock have been trending extremely negative recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evolus earned a media sentiment score of -5.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Evolus.

Evolus saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 5,700,000 shares, an increase of 11.8% from the December 15th total of 5,100,000 shares. Based on an average daily volume of 553,500 shares, the short-interest ratio is currently 10.3 days. Currently, 25.6% of the shares of the stock are sold short. View Evolus' Current Options Chain.

Some companies that are related to Evolus include Innoviva (INVA), Endo International (ENDP), BELLUS Health (BLUSF), TG Therapeutics (TGTX), Esperion Therapeutics (ESPR), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Nabriva Therapeutics (NBRV), Dicerna Pharmaceuticals (DRNA), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Athenex (ATNX), Myovant Sciences (MYOV) and ZEALAND PHARMA/S (ZEAL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA), Iovance Biotherapeutics (IOVA) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Global Retirement Partners LLC (0.07%), Janney Montgomery Scott LLC (0.06%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View Institutional Ownership Trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Corp Alphaeon, Lauren P Silvernail and Rui Avelar. View Insider Buying and Selling for Evolus.

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank and Global Retirement Partners LLC. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank and Vikram Malik. View Insider Buying and Selling for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $10.19.

Evolus has a market capitalization of $340.60 million. The company earns $-46,870,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Evolus employs 70 workers across the globe.View Additional Information About Evolus.

The official website for Evolus is http://www.evolus.com/.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]